312620-93-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-(4-(3,4-dichlorophenyl)-3,4-dihydronaphthalen-1(2H)-ylidene)methanamine is used as a potential therapeutic agent for its possible biological or pharmacological properties. Its unique structure may contribute to the development of new drugs, particularly in the treatment of various diseases and conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (S)-N-(4-(3,4-dichlorophenyl)-3,4-dihydronaphthalen-1(2H)-ylidene)methanamine serves as a valuable compound for synthesis and characterization studies. These studies are crucial for understanding its potential applications and activities, which could lead to the creation of novel therapeutic agents and advancements in drug discovery.

Upstream product

• 124379-29-9 (4S)-4-(3,4-dichlorophenyl)-1-tetralone 
• 74-89-5 methylamine 
• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 90-15-3 α-naphthol 
• 95-50-1 1,2-dichloro-benzene 
• 167026-37-1 (1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-ol 
• 167026-40-6 (1R,4S)-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-ol 

Downstream Products

• 79559-97-0 sertraline hydrochloride 
• 1271002-87-9 C₂₂H₂₅Cl₂NO₂ 
• 267884-85-5 cis-(1S,4S)-N-(tert-butoxycarbonyl)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 
• 79617-96-2 Sertraline 
• 79951-46-5 trans-(1R,4S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 

Relevant academic research and scientific papers

Chemoenzymatic Synthesis of Sertraline

A chemoenzymatic approach has been developed for the preparation of sertraline, an established anti-depressant drug. Ketoreductases (KREDs) were employed to yield a key chiral precursor. The bioreduction of the racemic tetralone exhibited excellent enantioselectivity (>99 % ee) and diastereomeric ratio (99:1) at 29 % conversion (the maximum theoretical yield is 50 %) after 7 hours. The resulting (S,S)-alcohol was efficiently oxidized to an enantiopure (S)-ketone, an immediate precursor of sertraline, by using sodium hypochlorite as oxidant and 2-azaadamantane N-oxyl (AZADO) as organocatalyst. Alternative routes aiming at the direct biocatalytic amination using imine reductases and transaminases were unsuccessful.

Asymmetric hydrogenation of N-Alkyl ketimines with phosphine-free, chiral, cationic Ru-MsDPEN catalysts

(Solvent) free and easy: A phosphine-free, chiral, cationic Ru-MsDPEN complex [(S,S)-1] is found to be an efficient catalyst for the enantioselective hydrogenation of a range of often-problematic N-alkyl ketimines (see scheme). This new method provides a more practical and greener synthetic approach to optically active amines, particularly N-alkyl amines, such as Sertraline.

Asymmetric reduction of substituted indanones and tetralones catalyzed by chiral dendrimer and its application to the synthesis of (+)-sertraline

A recoverable dendrimeric supported prolinol was used as a catalyst in the asymmetric reduction of indanones and tetralones to give separable cis and trans isomers up to 97% ee. This method was also applied in the enantioselective synthesis of the antidepressant drug (+)-sertraline.

Process for the preparation of ketimines

The present invention relates to a process for the preparation of compounds of formula (1), in which R1, R2and R3independently of one another are hydrogen, halogen , trifluoromethyl of or C1-C4alkoxy,